The genetic architecture of multiple myeloma (original) (raw)
Greipp, P. R. et al. International staging system for multiple myeloma. J. Clin. Oncol.23, 3412–3420 (2005). ArticlePubMed Google Scholar
Kyle, R. A. et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin. Proc.78, 21–33 (2003). ArticlePubMed Google Scholar
Kyle, R. A. et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N. Engl. J. Med.356, 2582–2590 (2007). ArticleCASPubMed Google Scholar
Akiyama, M. et al. Cytokines modulate telomerase activity in a human multiple myeloma cell line. Cancer Res.62, 3876–3882 (2002). CASPubMed Google Scholar
Chauhan, D. et al. Blockade of ubiquitin-conjugating enzyme CDC34 enhances anti-myeloma activity of Bortezomib/Proteasome inhibitor PS-341. Oncogene23, 3597–3602 (2004). ArticleCASPubMed Google Scholar
Damiano, J. S., Cress, A. E., Hazlehurst, L. A., Shtil, A. A. & Dalton, W. S. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood93, 1658–1667 (1999). CASPubMed Google Scholar
Hideshima, T. et al. Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood107, 4053–4062 (2006). ArticleCASPubMedPubMed Central Google Scholar
Mitsiades, C. S., Mitsiades, N. S., Munshi, N. C., Richardson, P. G. & Anderson, K. C. The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions. Eur. J. Cancer42, 1564–1573 (2006). ArticleCASPubMed Google Scholar
Chapman, M. A. et al. Initial genome sequencing and analysis of multiple myeloma. Nature471, 467–472 (2011). The first report of a myeloma genome, which demonstrated the complex and varied abnormalities that are seen in myeloma. ArticleCASPubMedPubMed Central Google Scholar
Gonzalez, D. et al. Immunoglobulin gene rearrangements and the pathogenesis of multiple myeloma. Blood110, 3112–3121 (2007). A comprehensive review of normal antibody generation and plasma cell development, detailing the changes that are seen in MGUS and myeloma. The importance of SHM and CSR is highlighted. ArticleCASPubMed Google Scholar
Bergsagel, P. L. & Kuehl, W. M. Critical roles for immunoglobulin translocations and cyclin D dysregulation in multiple myeloma. Immunol. Rev.194, 96–104 (2003). A review explaining the biological significance of chromosome 14 translocations in myeloma. ArticleCASPubMed Google Scholar
Hakim, O. et al. DNA damage defines sites of recurrent chromosomal translocations in B lymphocytes. Nature 7 Feb 2012 (doi:10.1038/nature10909).
Reimold, A. M. et al. Plasma cell differentiation requires the transcription factor XBP-1. Nature412, 300–307 (2001). ArticleCASPubMed Google Scholar
Iwakoshi, N. N. et al. Plasma cell differentiation and the unfolded protein response intersect at the transcription factor XBP-1. Nature Immunol.4, 321–329 (2003). ArticleCAS Google Scholar
Shaffer, A. L. et al. XBP1, downstream of Blimp-1, expands the secretory apparatus and other organelles, and increases protein synthesis in plasma cell differentiation. Immunity21, 81–93 (2004). ArticleCASPubMed Google Scholar
Davenport, E. L., Morgan, G. J. & Davies, F. E. Untangling the unfolded protein response. Cell Cycle7, 865–869 (2008). ArticleCASPubMed Google Scholar
Carrasco, D. R. et al. The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis. Cancer Cell11, 349–360 (2007). ArticleCASPubMedPubMed Central Google Scholar
Bagratuni, T. et al. XBP1s levels are implicated in the biology and outcome of myeloma mediating different clinical outcomes to thalidomide-based treatments. Blood116, 250–253 (2010). ArticleCASPubMed Google Scholar
Oracki, S. A., Walker, J. A., Hibbs, M. L., Corcoran, L. M. & Tarlinton, D. M. Plasma cell development and survival. Immunol. Rev.237, 140–159 (2010). ArticleCASPubMed Google Scholar
Radbruch, A. et al. Competence and competition: the challenge of becoming a long-lived plasma cell. Nature Rev. Immunol.6, 741–750 (2006). ArticleCAS Google Scholar
Chiecchio, L. et al. Timing of acquisition of deletion 13 in plasma cell dyscrasias is dependent on genetic context. Haematologica94, 1708–1713 (2009). ArticleCASPubMedPubMed Central Google Scholar
Carrasco, D. R. et al. High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell9, 313–325 (2006). ArticleCASPubMed Google Scholar
Walker, B. A. et al. A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value. Blood116, e56–e65 (2010). ArticleCASPubMed Google Scholar
Lopez-Corral, L. et al. The progression from MGUS to smoldering myeloma and eventually to multiple myeloma involves a clonal expansion of genetically abnormal plasma cells. Clin. Cancer Res.17, 1692–1700 (2011). ArticleCASPubMed Google Scholar
Cremer, F. W. et al. High incidence and intraclonal heterogeneity of chromosome 11 aberrations in patients with newly diagnosed multiple myeloma detected by multiprobe interphase FISH. Cancer Genet. Cytogenet.161, 116–124 (2005). ArticleCASPubMed Google Scholar
Walker, B. A. et al. Integration of global SNP-based mapping and expression arrays reveals key regions, mechanisms and genes important in the pathogenesis of multiple myeloma. Blood108, 1733–1743 (2006). ArticleCASPubMed Google Scholar
Anderson, K. et al. Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature469, 356–361 (2011). An important paper discussing the role of intraclonal variation in tumour biology. ArticleCASPubMed Google Scholar
Sahota, S. S., Leo, R., Hamblin, T. J. & Stevenson, F. K. Ig VH gene mutational patterns indicate different tumor cell status in human myeloma and monoclonal gammopathy of undetermined significance. Blood87, 746–755 (1996). CASPubMed Google Scholar
Ross, F. M. et al. Age has a profound effect on the incidence and significance of chromosome abnormalities in myeloma. Leukemia19, 1634–1642 (2005). ArticleCASPubMed Google Scholar
Akiyama, M. et al. Effects of oligonucleotide N3′→P5′ thio-phosphoramidate (GRN163) targeting telomerase RNA in human multiple myeloma cells. Cancer Res.63, 6187–6194 (2003). CASPubMed Google Scholar
Shammas, M. A. et al. Telomerase inhibition and cell growth arrest after telomestatin treatment in multiple myeloma. Clin. Cancer Res.10, 770–776 (2004). ArticleCASPubMed Google Scholar
Brennan, S. K. et al. Telomerase inhib ition targets clonogenic multiple myeloma cells through telomere length-dependent and independent mechanisms. PLoS ONE5, e12487 (2010). ArticlePubMedPubMed CentralCAS Google Scholar
McKenna, R. W. et al. Plasma cell neoplasms. In World Health Organization Classification of Tumors of Hematopoietic and Lymphoid Tissues (eds Swerdlow, S. H. et al.) 200–213 (IARC Press, 2008). Google Scholar
Anderson, K. C. New insights into therapeutic targets in myeloma. ASH Education Book2011, 184–190 (2011). Google Scholar
Walker, B. A. et al. Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma. Blood117, 553–562 (2011). The first report of global methylation changes from MGUS to PCL and within the myeloma cytogenetic subgroups. ArticleCASPubMed Google Scholar
Rasmussen, T. et al. Identification of translocation products but not K-RAS mutations in memory B cells from multiple myeloma patients. Haematologica95, 1730–1737 (2010). ArticleCASPubMedPubMed Central Google Scholar
Altieri, A., Chen, B., Bermejo, J. L., Castro, F. & Hemminki, K. Familial risks and temporal incidence trends of multiple myeloma. Eur. J. Cancer42, 1661–1670 (2006). ArticlePubMed Google Scholar
Broderick, P. et al. Common variation at 3p22.1 and 7p15.3 influences multiple myeloma risk. Nature Genet.44, 58–61 (2012). The first GWAS to identify myeloma disease susceptibility loci. ArticleCAS Google Scholar
Chesi, M. et al. Dysregulation of cyclin D1 by translocation into an IgH gamma switch region in two multiple myeloma cell lines. Blood88, 674–681 (1996). CASPubMed Google Scholar
Shaughnessy, J. Jr et al. Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma. Blood98, 217–223 (2001). ArticleCASPubMed Google Scholar
Hurt, E. M. et al. Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma. Cancer Cell5, 191–199 (2004). ArticleCASPubMed Google Scholar
Shou, Y. et al. Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma. Proc. Natl Acad. Sci. USA97, 228–233 (2000). ArticleCASPubMedPubMed Central Google Scholar
Avet-Loiseau, H. et al. Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors. Blood98, 3082–3086 (2001). ArticleCASPubMed Google Scholar
Chesi, M. et al. AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies. Cancer Cell13, 167–180 (2008). ArticleCASPubMedPubMed Central Google Scholar
Annunziata, C. M. et al. Frequent engagement of the classical and alternative NF-κB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell12, 115–130 (2007). ArticleCASPubMedPubMed Central Google Scholar
Carrasco, R. et al. Comprehensive genome-wide profile of regional gains and losses in multiple myeloma using array-CGH: The 1q21 amplification and potential role of the BCL-9 gene in multiple myeloma pathogenesis. Blood (ASH Annual Meeting Abstracts)104, 785 (2004). Google Scholar
Keats, J. J. et al. Promiscuous mutations activate the noncanonical NF-κB pathway in multiple myeloma. Cancer Cell12, 131–144 (2007). References 47 and 49 highlight the importance of NF-κB signalling in myeloma and the role that deregulation of the pathway has in myeloma pathogenesis. ArticleCASPubMedPubMed Central Google Scholar
Dickens, N. J. et al. Homozygous deletion mapping in myeloma samples identifies genes and an expression signature relevant to pathogenesis and outcome. Clin. Cancer Res.16, 1856–1864 (2010). ArticleCASPubMedPubMed Central Google Scholar
Boyd, K. D. et al. Mapping of chromosome 1p deletions in myeloma identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as being genes in regions associated with adverse survival. Clin. Cancer Res.17, 7776–7784 (2011). ArticleCASPubMedPubMed Central Google Scholar
Jenner, M. W. et al. Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myeloma. Blood110, 3291–3300 (2007). ArticleCASPubMed Google Scholar
Leone, P. E. et al. Deletions of CDKN2C in multiple myeloma: biological and clinical implications. Clin. Cancer Res.14, 6033–6041 (2008). ArticleCASPubMedPubMed Central Google Scholar
Gonzalez-Paz, N. et al. Tumor suppressor p16 methylation in multiple myeloma: biological and clinical implications. Blood109, 1228–1232 (2007). ArticleCASPubMed Google Scholar
Dib, A., Barlogie, B., Shaughnessy, J. D. Jr & Kuehl, W. M. Methylation and expression of the p16INK4A tumor suppressor gene in multiple myeloma. Blood109, 1337–1338 (2007). ArticleCASPubMed Google Scholar
Davis, R. E., Brown, K. D., Siebenlist, U. & Staudt, L. M. Constitutive nuclear factor-κB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J. Exp. Med.194, 1861–1874 (2001). ArticleCASPubMedPubMed Central Google Scholar
Onodera, N., McCabe, N. R. & Rubin, C. M. Formation of a hyperdiploid karyotype in childhood acute lymphoblastic leukemia. Blood80, 203–208 (1992). CASPubMed Google Scholar
Shaughnessy, J. Amplification and overexpression of CKS1B at chromosome band 1q21 is associated with reduced levels of p27Kip1 and an aggressive clinical course in multiple myeloma. Hematology.10 (Suppl. 1), 117–126 (2005). ArticleCASPubMed Google Scholar
Lee, W. et al. The mutation spectrum revealed by paired genome sequences from a lung cancer patient. Nature465, 473–477 (2010). ArticleCASPubMed Google Scholar
Aronson, L. I. et al. Autophagy is a key myeloma survival pathway that can be manipulated therapeutically to enhance apoptosis. ASH Annual Meeting Abstracts116, 4083 (2010). Google Scholar
Boyd, K. D. et al. High expression levels of the mammalian target of rapamycin inhibitor DEPTOR are predictive of response to thalidomide in myeloma. Leuk. Lymphoma51, 2126–2129 (2010). ArticlePubMed Google Scholar
Fazzari, M. J. & Greally, J. M. Epigenomics: beyond CpG islands. Nature Rev. Genet.5, 446–455 (2004). ArticleCASPubMed Google Scholar
Chi, P., Allis, C. D. & Wang, G. G. Covalent histone modifications — miswritten, misinterpreted and mis-erased in human cancers. Nature Rev. Cancer10, 457–469 (2010). ArticleCAS Google Scholar
Cedar, H. & Bergman, Y. Linking DNA methylation and histone modification: patterns and paradigms. Nature Rev. Genet.10, 295–304 (2009). ArticleCASPubMed Google Scholar
Nimura, K. et al. A histone H3 lysine 36 trimethyltransferase links Nkx2–5 to Wolf-Hirschhorn syndrome. Nature460, 287–291 (2009). ArticleCASPubMed Google Scholar
Kim, J. Y. et al. Multiple-myeloma-related WHSC1/MMSET isoform RE-IIBP is a histone methyltransferase with transcriptional repression activity. Mol. Cell Biol.28, 2023–2034 (2008). ArticleCASPubMedPubMed Central Google Scholar
Marango, J. et al. The MMSET protein is a histone methyltransferase with characteristics of a transcriptional corepressor. Blood111, 3145–3154 (2008). ArticleCASPubMedPubMed Central Google Scholar
Martinez-Garcia, E. et al. The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells. Blood117, 211–220 (2011). ArticleCASPubMedPubMed Central Google Scholar
Brito, J. L. et al. MMSET deregulation affects cell cycle progression and adhesion regulons in t(4;14) myeloma plasma cells. Haematologica94, 78–86 (2009). ArticleCASPubMed Google Scholar
van Haaften, G. et al. Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nature Genet.41, 521–523 (2009). ArticleCASPubMed Google Scholar
Avet-Loiseau, H. et al. Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). J. Clin. Oncol.28, 4630–4634 (2010). ArticleCASPubMed Google Scholar
Boyd, K. D. et al. The clinical impact and molecular biology of del(17p) in multiple myeloma treated with conventional or thalidomide-based therapy. Genes Chromosomes Cancer50, 765–774 (2011). ArticleCASPubMed Google Scholar
Pichiorri, F. et al. MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proc. Natl Acad. Sci. USA105, 12885–12890 (2008). ArticleCASPubMedPubMed Central Google Scholar
Pichiorri, F. et al. Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development. Cancer Cell18, 367–381 (2010). ArticleCASPubMedPubMed Central Google Scholar
Zenz, T. et al. Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial. Blood114, 2589–2597 (2009). ArticleCASPubMed Google Scholar
Benetatos, L. & Vartholomatos, G. Deregulated microRNAs in multiple myeloma. Cancer118, 878–887 (2012). ArticleCASPubMed Google Scholar
Chang, T. C. et al. Widespread microRNA repression by Myc contributes to tumorigenesis. Nature Genet.40, 43–50 (2008). ArticleCASPubMed Google Scholar
Boyd, K. D. et al. A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial. Leukemia26, 349–355 (2012). Evidence is presented highlighting the importance of combining cytogenetic abnormalities with other disease markers to accurately predict therapeutic response. ArticleCASPubMed Google Scholar
Ross, F. M. et al. The t(14;20) is a poor prognostic factor in myeloma but is associated with long-term stable disease in monoclonal gammopathies of undetermined significance. Haematologica95, 1221–1225 (2010). ArticlePubMedPubMed Central Google Scholar
Chauhan, D. et al. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-κB. Blood87, 1104–1112 (1996). CASPubMed Google Scholar
Moreaux, J. et al. BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood103, 3148–3157 (2004). ArticleCASPubMed Google Scholar
Neri, P. et al. Integrin β7-mediated regulation of multiple myeloma cell adhesion, migration, and invasion. Blood117, 6202–6213 (2011). ArticleCASPubMedPubMed Central Google Scholar
Annunziata, C. M. et al. A mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expression. Blood117, 2396–2404 (2011). ArticleCASPubMedPubMed Central Google Scholar
Wu, P. et al. A gene expression-based predictor for myeloma patients at high risk of developing bone disease on bisphosphonate treatment. Clin. Cancer Res.17, 6347–6355 (2011). ArticleCASPubMed Google Scholar
Bezieau, S. et al. High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis. Hum. Mutat.18, 212–224 (2001). ArticleCASPubMed Google Scholar
Braga, V. M., Betson, M., Li, X. & Lamarche-Vane, N. Activation of the small GTPase Rac is sufficient to disrupt cadherin-dependent cell-cell adhesion in normal human keratinocytes. Mol. Biol. Cell11, 3703–3721 (2000). ArticleCASPubMedPubMed Central Google Scholar
Morgan, G. J. et al. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet376, 1989–1999 (2010). ArticleCASPubMed Google Scholar
Tian, E. et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N. Engl. J. Med.349, 2483–2494 (2003). ArticleCASPubMed Google Scholar
Vallet, S. et al. Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease. Proc. Natl Acad. Sci. USA107, 5124–5129 (2010). ArticleCASPubMedPubMed Central Google Scholar
Avet-Loiseau, H. et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood109, 3489–3495 (2007). ArticleCASPubMed Google Scholar
Morgan, G. J. et al. Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation. Blood118, 1231–1238 (2011). ArticleCASPubMedPubMed Central Google Scholar
Paiva, B. et al. High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma. Blood119, 687–691 (2012). ArticleCASPubMed Google Scholar
Munshi, N. C. et al. Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood117, 4696–4700 (2011). An international consensus statement discussing the clinical impact of cytogenetic abnormalities. ArticleCASPubMedPubMed Central Google Scholar
Broyl, A. et al. Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients. Blood116, 2543–2553 (2010). ArticleCASPubMed Google Scholar
Zhan, F. et al. Gene expression profiling of human plasma cell differentiation and classification of multiple myeloma based on similarities to distinct stages of late-stage B-cell development. Blood101, 1128–1140 (2003). ArticleCASPubMed Google Scholar
Nair, B. et al. Gene expression profiling of plasma cells at myeloma relapse from tandem transplantation trial Total Therapy 2 predicts subsequent survival. Blood113, 6572–6575 (2009). ArticleCASPubMedPubMed Central Google Scholar
Chng, W. J., Glebov, O., Bergsagel, P. L. & Kuehl, W. M. Genetic events in the pathogenesis of multiple myeloma. Best Pract. Res. Clin. Haematol.20, 571–596 (2007). ArticleCASPubMedPubMed Central Google Scholar
Kassambara, A. et al. Genes with a spike expression are clustered in chromosome (sub)bands and spike (sub)bands have a powerful prognostic value in patients with multiple myeloma. Haematologica 18 Nov 2011 (doi:10.3324/haematol.2011.046821).
Shaughnessy, J. D. Jr et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood109, 2276–2284 (2007). ArticleCASPubMed Google Scholar
Morgan, G. J. et al. The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis. Blood119, 7–15 (2012). ArticleCASPubMed Google Scholar
Neben, K. et al. Administration of bortezomib before and after autologous stem-cell transplantation improves outcome in multiple myeloma patients with deletion 17p. Blood119, 940–948 (2012). ArticleCASPubMed Google Scholar
Stewart, A. K. Whole genome sequencing in high-risk myeloma. 13th Annual International Myeloma Workshop 2011[online] (2011). Google Scholar
Rettig, M. B. et al. VH gene usage in multiple myeloma: complete absence of the VH4.21 (VH4-34) gene. Blood 87, 2846–2852 (1996).
Nobuyoshi, M. et al. Increased expression of the c-myc gene may be related to the aggressive transformation of human myeloma cells. Br. J. Haematol.77, 523–528 (1991). ArticleCASPubMed Google Scholar
Perez-Rosado, A. et al. BCL6 represses NFκB activity in diffuse large B-cell lymphomas. J. Pathol.214, 498–507 (2008). ArticleCASPubMed Google Scholar